B. Riley Forecasts Stronger Earnings for PDS Biotechnology

PDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Stock analysts at B. Riley lifted their Q1 2025 earnings per share (EPS) estimates for shares of PDS Biotechnology in a research note issued to investors on Monday, April 21st. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of ($0.31) for the quarter, up from their prior estimate of ($0.34). The consensus estimate for PDS Biotechnology's current full-year earnings is ($1.20) per share. B. Riley also issued estimates for PDS Biotechnology's Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.05) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.81) EPS, FY2028 earnings at ($0.90) EPS and FY2029 earnings at $0.10 EPS.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.08.

Separately, HC Wainwright cut their target price on PDS Biotechnology from $21.00 to $13.00 and set a "buy" rating on the stock in a research note on Thursday, March 27th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $9.00.

PDS Biotechnology Stock Down 0.8 %

PDSB traded down $0.01 during trading on Thursday, reaching $1.24. The company had a trading volume of 184,961 shares, compared to its average volume of 486,811. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84. The company has a market cap of $56.29 million, a P/E ratio of -1.07 and a beta of 1.50. PDS Biotechnology has a 12 month low of $0.85 and a 12 month high of $4.42. The business's fifty day moving average price is $1.21 and its 200 day moving average price is $1.80.

Hedge Funds Weigh In On PDS Biotechnology

Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in shares of PDS Biotechnology by 331.0% in the fourth quarter. Renaissance Technologies LLC now owns 100,000 shares of the company's stock valued at $163,000 after buying an additional 76,800 shares during the last quarter. Virtu Financial LLC bought a new stake in PDS Biotechnology in the 4th quarter valued at $89,000. Two Sigma Investments LP lifted its holdings in PDS Biotechnology by 273.5% during the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company's stock valued at $107,000 after purchasing an additional 48,132 shares during the last quarter. Geode Capital Management LLC boosted its position in PDS Biotechnology by 9.8% during the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company's stock worth $1,586,000 after purchasing an additional 37,142 shares during the period. Finally, Blair William & Co. IL increased its holdings in shares of PDS Biotechnology by 29.4% in the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company's stock valued at $257,000 after purchasing an additional 35,757 shares during the last quarter. 26.84% of the stock is currently owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.